Business
Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders
Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Stren...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nMedison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nPETACH TIKVA, Israel, April 1, 2019\n\n\n\nKnight is failing, its CEO and Board are conflicted and shareholders are suffering as a result Medison's independent nominees are accomplished industry veterans who can objectively oversee and guide Knight More information on the director nominees and Medison's comprehensive plan for Knight, including plans to return at least $100 million of excess capital to Knight shareholders in the form of a special dividend or share buyback, is available at www.NewDayForKnight.com PETACH TIKVA, Israel, April 1, 2019 /CNW/ - Medison Biotech (1995) Ltd. (\"Medison\"), which together with its affiliates owns more than 10.4 million shares or 7.3% of Knight Therapeutics, Inc. (TSX:GUD) (\"Knight\" or the \"Company\"), today announced that it has nominated six exceptional pharmaceutical industry leaders (the \"Nominees\") for election to Knight's Board of Directors (the \"Board\") at the Company's 2019 annual general meeting, in accordance with the Company's Advanced Notice By-Law. Other than Medison's CEO, Meir Jakobsohn, who has served on the Knight Board since 2015, none of the Nominees has any ties to Knight or Medison. Each Nominee is committed to overseeing Knight for the benefit of all shareholders.  \n\"Knight has failed to create a specialty pharmaceutical company serving Canada and select rest-of-world markets,\" said Medison CEO Meir Jakobsohn. \"Shareholders, large and small, have invested their hard-earned money hoping, like me, that Knight would succeed. For three years, however, Knight's stock has floundered, and shareholders simply are not seeing the returns that all of us deserve. Rather than seizing opportunities and deploying the Company's ample capital to build a valuable and dynamic operating business, Knight has allowed shareholders' cash to stagnate while Knight meekly sits on the sidelines,...